Wave Life Sciences, Inc.
WVE Nasdaq· Pharmaceutical Preparations
Last close · Oct 28, 2026
$3.64
KIRA · Stoqly’s AI analyst, in plain words
- Wave Life Sciences, Inc. had $42.7M of revenue in fiscal 2025, down 60.5% on the year before. Over five years, revenue changed +16.3% a year on average.
- Its operating margin was −504.1%, down 402.2 pts: of every 100 in sales, about −504 is left after running the business.
- Wave Life Sciences, Inc. lost $204M in fiscal 2025.
- Free cash flow was −$188M in fiscal 2025, −440.5% of revenue.
Market cap
$743M
P/E
—
Revenue
$42.7M
Net income
−$204M
Free cash flow
−$188M
Operating margin
−504.1%
Wave Life Sciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−60.5%
No. Sales fell 60.5% last year.
Does it make a profit?
−478.3%
No. It lost money last year.
Does profit turn into cash?
−440.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Wave Life Sciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Wave Life Sciences, Inc.
- CIK
- 0001631574
Wave Life Sciences, Inc. · WVE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $41.0M | $3.6M | $113M | $108M | $42.7M |
| Revenue growth | 104.0% | −91.1% | 3,005.1% | −4.4% | −60.5% |
| Operating margin | −310.1% | −4,459.3% | −60.0% | −101.9% | −504.1% |
| Net income | −$122M | −$162M | −$57.5M | −$97.0M | −$204M |
| Net margin | −298.4% | −4,434.7% | −50.8% | −89.6% | −478.3% |
| Diluted EPS | −$2.36 | −$2.05 | −$0.54 | −$0.70 | −$1.21 |
| Cash | |||||
| Cash from operations | −$89.0M | −$128M | −$19.4M | −$151M | −$187M |
| Capital expenditure | $0.6M | $1.4M | $1.1M | $0.9M | $0.7M |
| Free cash flow | −$89.6M | −$129M | −$20.5M | −$152M | −$188M |
| FCF margin | −218.6% | −3,539.1% | −18.1% | −140.3% | −440.5% |
| Share count change | 32.1% | 52.2% | 34.5% | 30.3% | 22.0% |
| Debt and strength | |||||
| Cash and short-term investments | $151M | $88.5M | $200M | $302M | $602M |
| Shareholders' equity | $32.5M | −$45.1M | $39.6M | $210M | $518M |
| Current ratio | 2.5x | 1.4x | 1.3x | 2.9x | 6.5x |
| Returns and quality | |||||
| Return on equity | −212.1% | — | — | −77.9% | −56.2% |
| Return on tangible equity | −376.2% | — | −145.1% | −46.3% | −39.4% |
| Piotroski F-score | 3 | 1 | 3 | 1 | 2 |
| Altman Z'' | −13.5 | −28.1 | −12.5 | −7.0 | 1.1 |
Insiders bought, 12 months
$82.6M
2 insiders
Insiders sold, 12 months
$15.9M
11 insiders
Of sales under plans
98%
$15.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Wave Life Sciences, Inc. · WVE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.64 a share, the company is worth $743M.
Source: SEC EDGAR XBRL filings (CIK 0001631574). Data updated October 29, 2026. For information only — not investment advice. Check the original filings before relying on any figure.